May 27, 2026
1 min read

Viridian, awaiting FDA decision, taps WuXi Bio in eye drug supply deal

Viridian aims to challenge Amgen in a blockbuster market, and it’s now tapped Chinese CDMO giant WuXi Biologics in a manufacturing pact.

Leave a Reply

Your email address will not be published.

Previous Story

U.S. To Keep Ebola-Exposed Citizens In Kenya Under New Policy MedNews

Next Story

STAT+: Heart patch engineered from stem cells revved up weakened hearts

Previous Story

U.S. To Keep Ebola-Exposed Citizens In Kenya Under New Policy MedNews

Next Story

STAT+: Heart patch engineered from stem cells revved up weakened hearts

Latest from Blog

Go toTop